Email updates

Keep up to date with the latest news and content from BMC Palliative Care and BioMed Central.

Open Access Research article

Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer

Nikolaos Barbetakis1*, Michalis Vassiliadis2, Konstantinos Kaplanis3, Rosalia Valeri4 and Christodoulos Tsilikas1

Author Affiliations

1 Cardiothoracic Surgery Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece

2 Anaesthesiology Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece

3 Gynaecologic Oncology Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece

4 Cytopathology Department, Theagenio Cancer Hospital, A. Simeonidi 2, Thessaloniki, Greece

For all author emails, please log on.

BMC Palliative Care 2004, 3:4  doi:10.1186/1472-684X-3-4

Published: 9 September 2004

Abstract

Background

Advanced ovarian cancer is the leading non-breast gynaecologic cause of malignant pleural effusion. Aim of this study was to assess the efficacy of mitoxantrone sclerotherapy as a palliative treatment of malignant pleural effusions due to ovarian cancer.

Methods

Sixty women with known ovarian cancer and malignant recurrent symptomatic pleural effusion were treated with chest tube drainage followed by intrapleural mitoxantrone sclerotherapy. Survival, complications and response to pleurodesis were recorded. The data are expressed as the mean ± SEM and the median.

Results

The mean age of the entire group was 64 ± 11,24 years. The mean interval between diagnosis of ovarian cancer and presentation of the effusion was 10 ± 2,1 months. Eighteen patients (30%) had pleural effusion as the first evidence of recurrence. The mean volume of effusion drained was 1050 ± 105 ml and chest tube was removed within 4 days in 75% of patients. There were no deaths related to the procedure. Side effects of chemical pleurodesis included fever (37–38,5°C) chest pain, nausea and vomiting. At 30 days among 60 treated effusions, there was an 88% overall response rate, including 41 complete responses and 12 partial responses. At 60 days the overall response was 80% (38 complete responses and 10 partial responses). The mean survival of the entire population was 7,5 ± 1,2 months.

Conclusions

Mitoxantrone is effective in the treatment of malignant pleural effusion secondary to ovarian cancer without causing significant local or systemic toxicity.